Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10479181 | 0.88 | LMNA (0.62) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL11013946 | 0.79 | ALOX15 (0.30) | TSHR | |
| Orotic Acid SCHEMBL185887 | 0.79 | ALOX15 (0.50) | LMNATSHRKDM4EALDH1A1 | |
| SCHEMBL27302558 | 0.78 | LMNA (0.47) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL27410251 | 0.78 | LMNA (0.47) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL12086579 | 0.77 | LMNA (0.31) | LMNA | |
| SCHEMBL14537021 | 0.77 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL28051438 | 0.77 | LMNA (0.45) | LMNAADORA3TSHRMC4RADRA1A | |
| Water SCHEMBL27489111 | 0.77 | LMNA (0.45) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL27944461 | 0.75 | LMNA (0.44) | LMNAADORA3TSHRMC4RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | claimed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| CN-107530343-A | Triazolylpyridine ketones compound as PDE2 inhibitor | 默沙东公司 | 2018-01-02 | — | — | CN | disclosed |
| WO-2017113288-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| EP-0073463-B1 | INSERTION COMPOUNDS, INTERCALATION COMPOUNDS AND SOLID SOLUTIONS OF COLOURED METALLIC ORGANIC DERIVATIVES | BAYER AG (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0093306-A1 | Methods for the preparation of azo compounds, and azo compounds | BAYER AG (DE) | 1983-11-09 | — | — | EP | disclosed |
| EP-0073463-A1 | Insertion compounds, intercalation compounds and solid solutions of coloured metallic organic derivatives | BAYER AG (DE) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885ADORA3 2114/4885TSHR 3150/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | LMNA 2222/4885ADORA3 2458/4885TSHR 4272/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | LMNA 4249/4885ADORA3 911/4885TSHR 641/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | LMNA 2005/4885ADORA3 3616/4885TSHR 2931/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | LMNA 2005/4885ADORA3 3616/4885TSHR 2931/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | LMNA 4249/4885ADORA3 911/4885TSHR 641/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885ADORA3 2114/4885TSHR 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.